Navigation Links
Poniard Pharmaceuticals Reports Third Quarter 2010 Financial Results
Date:11/9/2010

oned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. The Company undertakes no obligation to update any forward-looking statement to reflect new information, events or circumstances after the date of this release or to reflect the occurrence of unanticipated events.Poniard Pharmaceuticals, Inc.Condensed Consolidated Statements of Operations(In thousands, except per share data)(Unaudited)Three Months Ended September 30,Nine Months Ended September 30,2010200920102009Revenues$
-$
-Operating expenses:Research and development (Note 1)8915,0567,87018,545General and administrative (Note 1)5,0604,14213,74710,929Restructuring & asset impairment--1,6261,056  Total operating expenses5,9519,19823,24330,530Loss from operations(5,951)(9,198)(23,243)(30,530)Other income (expense), net(498)(679)(1,641)(2,017)Net loss(6,449)(9,877)(24,884)(32,547)Preferred stock dividends(48)(125)(688)(375)Loss applicable to common shares$
(6,497)$
(10,002)$
(25,572)$
(32,922)Loss per share:Basic and diluted$
(0.13)$
(0.29)$
(0.55)$
(0.95)Shares used in calculation of loss per share:Basic and diluted48,23734,76946,35734,723Condensed Consolidated Balance Sheets(In thousands)September 30, 2010December 31, 2009(Unaudited)(Note 2)ASSETS:Cash and investment securities$
23,345$
43,389Cash - restricted158281Facilities and equipment, net73219Licensed products, net6,6817,592Other assets887961  Total assets$
31,144$
52,442LIABILITIES AND SHAREHOLDERS' EQUITY:Current liabilities$
2,425$
7,127Long term liabilities6,58511,671Shareholders' equity12,13423,644  Total liabilities and shareholders' equity$
31,144$
52,442Note 1:  Patent related legal expenses are included in G&A expenses. The 2009 expenses have been reclassified above to conform to this presentation.Note 2:  Derived from audited financial statements included in the Company’s Annual Report on For
'/>"/>
SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Poniard Pharmaceuticals to Present Updated Results of Picoplatin Phase 2 Small Cell Lung Cancer Trial at 12th World Conference on Lung Cancer
2. Poniard Pharmaceuticals Announces Updated Results of Picoplatin Phase 2 Trial Demonstrating Survival Benefit in Small Cell Lung Cancer Patients
3. Poniard Pharmaceuticals Receives FDA Fast Track Designation for Picoplatin for Treatment of Small Cell Lung Cancer
4. Poniard Pharmaceuticals Initiates Randomized Phase 2 Trial of Picoplatin for First-Line Treatment of Metastatic Colorectal Cancer
5. Poniard Pharmaceuticals Provides Year-End Clinical Update at 2007 Lazard Capital Markets Healthcare Conference
6. Poniard Pharmaceuticals Announces Picoplatin Safety Data in Colorectal Cancer
7. Poniard Pharmaceuticals Announces Positive First-line Phase 1 Safety and Efficacy Data With Picoplatin in Metastatic Prostate Cancer Patients
8. Poniard Pharmaceuticals Announces Clinical Data From Picoplatin Oral Phase 1 to Be Presented at the American Association of Cancer Research Annual Meeting
9. Poniard Pharmaceuticals Announces Commercial Manufacturing Agreement With W. C. Heraeus GmbH for Picoplatin
10. Poniard Pharmaceuticals Announces Presentation of Clinical Data From Picoplatin Phase 2 Small Cell Lung Cancer Trial to be Presented at 1st IASLC-ESMO European Lung Cancer Conference
11. Poniard Pharmaceuticals Oral Picoplatin Demonstrates Positive Bioavailability in Ongoing Phase 1 Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)...  Unilife Corporation ("Unilife" or "Company") (NASDAQ: ... of injectable drug delivery systems, today announced an ... facilities in response to increasing demand from pharmaceutical ... During the fourth quarter of fiscal year 2014, ... expenditures and R&D above normal quarterly investments. ...
(Date:7/30/2014)... N.Y. , July 30, 2014 /PRNewswire-iReach/ -- ... -based medical device company, has announced today ... the velox CD™ Vascular Closure Device. Velox CD™ ... immediate hemostasis following percutaneous femoral procedures. The single ... broadly ranging in size from 5F to 8F.  ...
(Date:7/30/2014)... -- InnoPharma, Inc. today announced the first generic launch of ... injection), in Canada.  Olanzapine is indicated for the rapid ... schizophrenia or bipolar I mania. As the ... into an agreement with Sandoz Canada Inc., pursuant to ... market and distribute Olanzapine Injection in Canada ...
Breaking Medicine Technology:Unilife Accelerates Investment to Meet Increasing Demand from New and Existing Customers 2Unilife Accelerates Investment to Meet Increasing Demand from New and Existing Customers 3Unilife Accelerates Investment to Meet Increasing Demand from New and Existing Customers 4Unilife Accelerates Investment to Meet Increasing Demand from New and Existing Customers 5Transluminal Technologies receives CE Mark approval for velox CD(TM) vascular closure device 2InnoPharma Announces Launch of Olanzapine for Injection, 10mg/vial in Canada 2
... Ill., Dec. 21, 2010 The American Veterinary Medical Association ... new federal guidelines on a useful and effective induction agent, ... making propofol a Schedule IV drug.  In a letter to ... the DEA keep this effective drug, which typically causes few ...
... Dec. 21, 2010 Based on its recent ... & Sullivan recognizes Cambridge, Mass.-based Semprus BioSciences with ... Award for Surface Functionalization Technologies . The company,s ... designed to reduce the complications associated with implanted ...
Cached Medicine Technology:AVMA Offers Important Guidance to DEA on New Controls for Induction Agent—Propofol 2Frost & Sullivan Presents the 2010 North American Enabling Technology of the Year Award for Surface Functionalization Technologies to Semprus BioSciences 2Frost & Sullivan Presents the 2010 North American Enabling Technology of the Year Award for Surface Functionalization Technologies to Semprus BioSciences 3
(Date:7/30/2014)... (PRWEB) July 30, 2014 Volunteers from ... to counter drug abuse this summer with massive distribution ... , You can find these volunteers on Strøget, the ... residents alike for its shopping and its ambiance, some ... on a typical summer day. , These activities ...
(Date:7/30/2014)... mutationslong known to fuel cancer as well as evolutionary ... rare events that occur randomly throughout the genome. , ... involves the formation of multiple mutations that arise simultaneously ... of clustered mutations are frequently found in regions where ... the journal Cell Reports , may one day ...
(Date:7/30/2014)... MA (PRWEB) July 30, 2014 ... of authentication, access management and secure communications solutions ... Imprivata OneSign ® is the most widely selected ... McKesson Paragon or Horizon electronic medical records (EMR) ... increase of about 11 percent in the last ...
(Date:7/30/2014)... IN (PRWEB) July 30, 2014 ... the opening of its new Carmel office on July ... staff will finally be moving to the state-of-the-art suite, ... cozy and innovative space will allow for one-on-one patient ... cosmetic surgery experience. , Dr. Hamilton’s new office-suite ...
(Date:7/30/2014)... caught it early" is possibly the best news a ... diagnosis. Combating cancer in its earliest stages, when the ... body, gives patients the best chances of survival. ... forms of cancer are touted for saving lives through ... as a precautionary measure, especially for high-risk patients. But ...
Breaking Medicine News(10 mins):Health News:Biologists describe mechanism promoting multiple DNA mutations 2Health News:Imprivata Achieves 51 Percent Single Sign-on Market Share Amongst U.S. Hospitals Using McKesson Paragon or Horizon EMR Systems, According to HIMSS Analytics 2Health News:Hamilton Facial Plastic Surgery Opens New Carmel Office 2Health News:UK psychologist creates patient tool to assist with lung cancer screening decision 2Health News:UK psychologist creates patient tool to assist with lung cancer screening decision 3
... common among prisoners than among the general population of Thailandone ... found that 25% of prisoners who agreed to be tested ... in the national population. ,But Thailands prisons, say ... and severe budgetary constraints that impede the effective delivery of ...
... have been deployed worldwide to provide early detection of ... ,New methods that improve the overall detection capabilities of ... most surveillance systems do not hold up when there ... by public-health crises and major public events, such as ...
... the Archives of Internal Medicine journal, Obese or overweight ... risk of developing tuberculosis than those at a normal ... poverty and undernutrition in both developed and developing countries. ... associated with a wide range of chronic degenerative conditions, ...
... of antidepressant medications known as selective serotonin reuptake inhibitors ... loss in older men and women. Selective serotonin ... that transports serotonin, a neurotransmitter involved in sleep and ... in bone as well, raising the possibility that SSRIs ...
... of Washington shows that the work intended for global ... . ,The research was conducted by a UW ... professor in the School of Public Health and Community ... and Sally Weatherford, finance and administration director of the ...
... section does not affect infants health. The babies delivered ... early in life according to a new study. ... Hong Kong researchers found that babies delivered by C-section ... visits during their first 18 months of life. ...
Cached Medicine News:Health News:Obesity is Related to Lower Tuberculosis Risk 2Health News:Antidepressents may Lower Bone Density in Older People 2Health News:Antidepressents may Lower Bone Density in Older People 3Health News:Global Health Enriching the States Economy 2Health News:C- Section Does Not Affect an Infants Health 2
This ENDOLOOP suture has a suture type - 0 PDSII and a 1.5 inch diameter....
... long ligature inserted into a plastic tube. The plastic ... the other. The suture protrudes from the narrow end ... knot which becomes secure after the device is activated. ... the scored end of the plastic tube. The scored ...
... Panel is an enzyme immunoassay used for ... (glutamate dehydrogenase) and toxin A in human ... an aid in the diagnosis of C. ... the Triage Microbiology product line, designed to ...
ELISA for the detection of C. difficile toxin A in stool specimens...
Medicine Products: